Reply to correspondence on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway” Eun Ji Jang, Pil Soo Sung Clinical and Molecular Hepatology.2026; 32(1): e115. CrossRef
Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography: A Potential Imaging Biomarker for Predicting Response to Combination Immunotherapy in Hepatocellular Carcinoma Masatoshi Kudo Liver Cancer.2025; 14(5): 511. CrossRef
Background/Aims Previously, we advocated the importance of classifying hepatocellular carcinoma (HCC) based on physiological functions. This study aims to classify HCC by focusing on liver-intrinsic metabolism and glycolytic pathway in cancer cells.
Methods Comprehensive RNA/DNA sequencing, immunohistochemistry, and radiological evaluations were performed on HCC tissues from the training cohort (n=136) and validated in 916 public samples. HCC was classified using hierarchical clustering and compared with previous molecular, histopathological, and hemodynamic classifications.
Results Liver-specific metabolism and glycolysis are mutually exclusive and were divided into two major subclasses: The “rich metabolism” subclass (60.3%) is characterized by enhanced bile acid and fatty acid metabolism, wellto-moderate differentiation, microtrabecular or pseudoglandular pattern, and homogeneous arterial-phase hyperenhancement (APHE), corresponding to Hoshida S3 with favorable prognosis. In IL6-JAK-STAT3-high (25.0%) conditions, upregulated ALB expression, enhanced gluconeogenesis and urea cycle activity, and an inflammatorymicroenvironment are observed. Conversely, the Wnt/β-catenin-high environment (19.9%) features elevated GLUL, APOB and CYP3A4 expression, frequent CTNNB1 (D32–S37) mutations, and an immune-desert/excluded phenotype. The “glycolysis” subclass (39.7%), characterized by histopathological dedifferentiation and downregulated liver-specific metabolism, encompasses subclasses with PI3K/mTOR (20.6%) and NOTCH/TGF-β (19.1%) signaling. These often exhibit TP53 mutations, macrotrabecular massive or compact patterns, inhomogeneous/rim-APHE, and high expression of hypoxia-inducible factors and glucose transporters, corresponding to Hoshida S1/2 with poor prognosis.
Conclusions The loss of liver-specific metabolism correlates with morphological dedifferentiation, indicating cellular dedifferentiation may exhibit both physiological and pathological duality. Key signaling pathways involved in the maturation process from fetal to adult liver and zonation program may play a critical role in defining HCC diversity.
Citations
Citations to this article as recorded by
Correspondence to editorial on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway” Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo Clinical and Molecular Hepatology.2026; 32(1): e79. CrossRef
Molecular stratification of hepatocellular carcinoma by metabolic-signaling pathways guides precision immunotherapy and TACE therapy Binghua Li, Yanchao Xu, Yican Zhu, Yukun Zhang, Zijie Wu, Tianci Luo, Laizhu Zhang, Weiwei Hu, Decai Yu Clinical and Molecular Hepatology.2026; 32(1): e16. CrossRef
Reply to correspondence on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway” Eun Ji Jang, Pil Soo Sung Clinical and Molecular Hepatology.2026; 32(1): e115. CrossRef
A novel link between tumor cell metabolism and patient prognosis: Editorial on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway” Eun Ji Jang, Pil Soo Sung Clinical and Molecular Hepatology.2026; 32(1): 420. CrossRef
Zonation, Zonation, Zonation: The Real Estate of the Liver Tyler M. Yasaka, Chang Kyung Kim, Vik Meadows, Satdarshan P. Monga
Annual Review of Pathology: Mechanisms of Disease
.2026; 21(1): 185. CrossRef
Single-cell RNA sequencing and spatial transcriptomic analysis reveal a distinct population of G6PD+ cells with aberrant bile acid metabolism in hepatocellular carcinoma Xing Jiang, Haiyan Quan, Ting Yin, Hailun Yao, Yajun Li, Bin Peng, Xinye Yuan, Weiguang Zeng, Honghui Chen, Rong Li Frontiers in Immunology.2026;[Epub] CrossRef
Overexpression of S100 Calcium-Binding Protein A2 is Associated With Poor Prognosis in Hepatocellular Carcinoma Xiaopeng Chen, Shaoqing Ma, Wenlong Zeng, Chuiguo Huang, Jianyang Guo Cancer Control.2026;[Epub] CrossRef
Correspondence to letter to the editor on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway” Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo Clinical and Molecular Hepatology.2026; 32(2): e241. CrossRef
Critical flaws in the molecular classification of HCC based on metabolic zonation: Letter to the editor on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway” Yongzhi Xie, Xiangyu Zhu, Qi Liang Clinical and Molecular Hepatology.2026; 32(2): e144. CrossRef
Clinical applications of immunogenomics in hepatocellular carcinoma James K. Carter, Daniel C. Cameron, Augusto Villanueva Clinical and Molecular Hepatology.2026; 32(2): 511. CrossRef
Unveiling the Intricate Dance: Signaling Pathways in Liver Cancer Metabolism and Immunity Yichi Xu, Bo Wen, Dai Zhang, Fangxin Tang, Shu Liu Current Oncology Reports.2026;[Epub] CrossRef
Integrative Profiling of Metabolic CYP Expression, DNA Mutation Rates, and Immune Cell Infiltration for Survival Prognosis in Hepatocellular Carcinoma Mona Dawood, Axel Guthart, Ednah Ooko, Ralf Weiskirchen, Thomas Efferth, Joelle C. Boulos Livers.2026; 6(3): 50. CrossRef
Metabolic Reprogramming at the Tumor–Immune Interface in Hepatocellular Carcinoma Weiming Zhao, Ping Li Cells.2026; 15(15): 1357. CrossRef
Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography: A Potential Imaging Biomarker for Predicting Response to Combination Immunotherapy in Hepatocellular Carcinoma Masatoshi Kudo Liver Cancer.2025; 14(5): 511. CrossRef
Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma Hideki Iwamoto, Hironori Koga, Takumi Kawaguchi Clinical and Molecular Hepatology.2026; 32(1): e38. CrossRef
Correspondence to editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma” Rong-Qi Sun, Shao-Lai Zhou Clinical and Molecular Hepatology.2025; 31(2): e192. CrossRef
Curative response to combined targeted-immunotherapy for post-hepatectomy lymph node metastasis in sarcomatoid hepatocellular carcinoma: case report and literature review Pan Liu, Song Zhang, Xiao-Ming Xin, Min Jing, Lie-Dong Wen, Xin Xiang, Shun-Hai Liu Frontiers in Oncology.2025;[Epub] CrossRef
Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma Hideki Iwamoto, Hironori Koga, Takumi Kawaguchi Clinical and Molecular Hepatology.2026; 32(1): e38. CrossRef
Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial” Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee Clinical and Molecular Hepatology.2025; 31(1): e84. CrossRef
T lymphocyte-based immune response and therapy in hepatocellular carcinoma: focus on TILs and CAR-T cells Thikra Majid Muhammed, Saade Abdalkareem Jasim, Ahmed Hussein Zwamel, Safia Obaidur Rab, Suhas Ballal, Abhayveer Singh, Anima Nanda, Subhashree Ray, Ahmed Hjazi, Hatif Abdulrazaq Yasin Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(8): 10007. CrossRef
Genetic insights into sarcomatoid hepatocellular carcinoma: Critical role of ARID2 in pathogenesis and immune feature: Editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma” Naoshi Nishida Clinical and Molecular Hepatology.2025; 31(2): 635. CrossRef
Addressing the Complexities of Pre-Liver Transplant Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: A Response to Recent Commentaries Mohammad Saeid Rezaee-Zavareh, Zhiyong Guo, Ju Dong Yang Journal of Hepatology.2024;[Epub] CrossRef
Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma Hideki Iwamoto, Hironori Koga, Takumi Kawaguchi Clinical and Molecular Hepatology.2026; 32(1): e38. CrossRef
Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study Yuri Cho, Jeong-Hoon Lee, Baek-Yeol Ryoo, Ho Yeong Lim, Dong Eun Lee, Bo Hyun Kim, Joong-Won Park Gut and Liver.2026; 20(4): 624. CrossRef
Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study” Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim Clinical and Molecular Hepatology.2024; 30(4): 1005. CrossRef
Systemic hematologic, metabolic, and inflammatory dysregulation in liver cirrhosis and hepatocellular carcinoma: diagnostic utility of novel indices in an Egyptian cohort Dalia E. Sherief, Hadeer Hamdy Shehata, Nahla Nosair, Amira A. A. Othman, Mohamed W. Saleh, Emad Sadaka, Rasha Elgamal BMC Gastroenterology.2026;[Epub] CrossRef
Integrative transcriptomic analysis reveals miR-26a-5p downregulation and a potential predictive gene signature for the progression of metabolic liver disease Andrei Sorop, Alina-Veronica Ghionescu, Diana Larisa Ancuța, Maria-Gabriela Croitoru, Cristin Coman, Daniela Lixandru, Simona Olimpia Dima Frontiers in Cell and Developmental Biology.2026;[Epub] CrossRef
Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients with Early-Stage Hepatocellular Carcinoma Dong Hyun Kim, Eun Min Kim, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Gi Hong Choi, Sang Hoon Ahn, Hye Won Lee, Do Young Kim Cancers.2025; 17(4): 566. CrossRef
Biosocial Determinants of Health Among Patients with Chronic Liver Disease and Liver Cancer Tagari Samanta, Jun Hyoung Park, Benny Abraham Kaipparettu Cancers.2025; 17(5): 844. CrossRef
Global, regional, and national burden of NASH related liver cancer in adults aged 45 and above: an analysis from the GBD 2021 and forecast to 2050 Jianing Shi, Xuan Wu, Jiali Yu, Qingli Zhou Frontiers in Nutrition.2025;[Epub] CrossRef
Large duct primary sclerosing cholangitis with or without inflammatory bowel disease in Saudi patients Hamdan S. AlGhamdi, Nawaf M. AlYahya, Ibrahim M. Bahabri, Majed A. Al Ashaikh, Abdulrahman K. Habib, Abdulaziz A. AlAhmary, Nuha Al Ajlan, Abdulrahman I. AlAbdulgader, Abduljaleel M. Alalwan, Faisal M. Sanai Saudi Journal of Gastroenterology.2025; 31(6): 356. CrossRef
Non-Viral Hepatocellular Carcinoma with Normal Alpha-Fetoprotein but Elevated CA19-9 in an Older Patient with Obesity: A Case Report Seung Hun Lee, Mi Soo Kim, Jeong Gyu Lee Korean Journal of Geriatrics & Gerontology.2025; 26(3): 147. CrossRef
Nanoquercetin and Extracellular Vesicles as Potential Anticancer Therapeutics in Hepatocellular Carcinoma Alok Raghav, Goo Bo Jeong Cells.2024; 13(7): 638. CrossRef
Hepatitis B-related hepatocellular carcinoma: classification and prognostic model based on programmed cell death genes Jinyue Tian, Jiao Meng, Zhenkun Yang, Li Song, Xinyi Jiang, Jian Zou Frontiers in Immunology.2024;[Epub] CrossRef
Burden of uterine cancer in China from 1990 to 2021 and 15-year projection: a systematic analysis and comparison with global levels Zhan Lin, Mei Gan, Xiangping Wang, Zhonghua Su Reproductive Health.2024;[Epub] CrossRef
Recent Trends in Liver Cancer: Epidemiology, Risk Factors, and Diagnostic Techniques Shivani R Kale, Geeta Karande, Anand Gudur, Aishwarya Garud, Monika S Patil, Satish Patil Cureus.2024;[Epub] CrossRef
Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy” Seren M. Gedallovich, Paul Y. Kwo Clinical and Molecular Hepatology.2024; 30(4): 1050. CrossRef
The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(1): 99. CrossRef
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith Clinical and Molecular Hepatology.2023; 29(2): 433. CrossRef
Occurrence of Liver Cancer in People without Traditional Risk Factors Junho Choi, Joohyun Park, Jae Kwang Lee, Kyunghee Cho Korean Journal of Clinical Geriatrics.2023; 24(1): 41. CrossRef
The Role of the Gut Microbiome and the Hepatic Axis in the Pathogenesis of Metabolic Syndrome and Therapeutics K. P. Divya, Parneet Hari, Navjot Kanwar, Navita Aggarwal, Preeti Singh Dhoat, Lu Liu, Abhinav Kanwal, Shailendra Pratap Singh, Jiong Yu Advanced Gut & Microbiome Research.2023; 2023: 1. CrossRef
Bursatella leachii Purple Ink Secretion Concentrate Exerts Cytotoxic Properties against Human Hepatocarcinoma Cell Line (HepG2): In Vitro and In Silico Studies Zeyad I. Alehaideb, Anuradha Venkatraman, Mahadev Kokane, Syed Ali Mohamed, Saranya Rameshbabu, Rasha S. Suliman, Sahar S. Alghamdi, Hamad Al-Eidi, Bandar Alghanem, Maha-Hamadien Abdulla, Sabine Matou-Nasri Molecules.2022; 27(3): 826. CrossRef
The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study Yuri Cho, Eun Ju Cho, Jeong-Ju Yoo, Young Chang, Goh Eun Chung, In Young Choi, Sang-Hyun Park, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu Frontiers in Oncology.2022;[Epub] CrossRef
Association between metabolic syndrome, C-reactive protein, and the risk of primary liver cancer: a large prospective study Mengmeng Song, Tong Liu, Hai Liu, Qi Zhang, Qingsong Zhang, Yiming Wang, Xiangming Ma, Liying Cao, Hanping Shi BMC Cancer.2022;[Epub] CrossRef
Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease Joo Hyun Oh, Je Hee Lee, Min Seok Cho, Hyeree Kim, Jongsik Chun, Joon Hyeok Lee, Yeup Yoon, Wonseok Kang Nutrients.2021; 13(3): 1013. CrossRef
Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim Cancers.2021; 13(14): 3424. CrossRef
Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro Translational Oncology.2021; 14(9): 101158. CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1 Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef
Circulating tumour DNA for a minimal residual disease assessment and recurrence risk in hepatocellular carcinoma: a systematic review and meta-analysis Isabella R. Buonopane, Erick F. Saldanha, Júnior Samuel Alonso de Menezes, Lucas Diniz da Conceição, Camila Mariana de Paiva Reis, Luís Felipe Leite, Thiago Francischetto, Renata D’Alpino Peixoto, Tiago Biachi de Castria British Journal of Cancer.2026; 134(5): 699. CrossRef
Recurrence risk prediction model for hepatitis B virus-associated hepatocellular carcinoma patients: a systematic review and meta-analysis Ke-Hao Zhao, Jiajun Liu, Yun-Shan Chen, Wen-Ting Yi, Juan-Juan Liu, Ying Zeng Frontiers in Oncology.2026;[Epub] CrossRef
Reappraising the T category in hepatocellular carcinoma: Prognostic impact of the type and extent of vascular invasion Shigeaki Kurihara, Hiroji Shinkawa, Ryota Tanaka, Sadaaki Nishimura, Jun Tauchi, Genki Watanabe, Masahiko Kinoshita, Kohei Nishio, Kenjiro Kimura, Takeaki Ishizawa Surgery.2026; 197: 110403. CrossRef
IL‑6/STAT3 signaling pathway‑mediated apoptosis induced by medical ozone water in liver cancer: A mechanistic study Shixiang Qiu, Chao Chen, Zihang Zhang, Ningjun Yu, Jingang Huang, Dan Deng, Liming Zhong Biomedical Reports.2026; 25(2): 1. CrossRef
Comprehensively Analyzing the Impact of Comprehensive Complication Index on the Long-term Prognostic for Patients with Hepatocellular Carcinoma After Hepatectomy Zi-Yang Bao, Yu-Ting Xiao, Wen-Feng Lu, Kai Wang, Jian-Yong Yuan, Yang Yu, Kai-Di Wang, Zi-Chen Yu, Zheng-Kang Fang, Zhe-Jin Shi, Dong-Sheng Huang, Jun-Wei Liu, Cheng-Wu Zhang, Lei Liang Current Problems in Surgery.2026; : 102126. CrossRef
Prognostic nomogram based on coagulation for individualized prediction after radical resection of hepatocellular carcinoma Ming Lu, Haibo Yuan, Mengjie Wu, Heng Li, Congyin Tu, Kongwang Hu European Journal of Medical Research.2025;[Epub] CrossRef
Statistical Cure After Hepatectomy for Hepatitis B Virus-Associated Hepatocellular Carcinoma: A Risk-Stratification Model Yi-Fan Li, Lan-Qing Yao, Chao Li, Hong Ren, Jin-Bo Gong, Han Wu, Li-Hui Gu, Ying-Jian Liang, Yu-Ze Yang, Kong-Ying Lin, Zi-Qiang Li, Qi-Xuan Zheng, Ting-Hao Chen, Ya-Hao Zhou, Hong Wang, Hong-Wei Guo, Jia-Hao Xu, Zhong Chen, Feng Shen, Ming-Da Wang, Tian Annals of Surgical Oncology.2025; 32(6): 4396. CrossRef
Magnetic resonance elastography as a preoperative assessment for predicting intrahepatic recurrence in patients with hepatocellular carcinoma Jeong Hyun Lee, Jeong Ah Hwang, Kyowon Gu, Jaeseung Shin, Seungchul Han, Young Kon Kim Magnetic Resonance Imaging.2024; 109: 127. CrossRef
Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Myung Ji Goh, Wonseok Kang, Seung Up Kim European Journal of Gastroenterology & Hepatology.2023; 35(2): 191. CrossRef
Development and validation of a nomogram for survival prediction in hepatocellular carcinoma after partial hepatectomy Yang Lu, Shuang Ren, Jianning Jiang BMC Surgery.2023;[Epub] CrossRef
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi Clinical and Molecular Hepatology.2023; 29(3): 593. CrossRef
Diagnosis of primary clear cell carcinoma of the liver based on Faster region-based convolutional neural network Bin Liu, Jianfei Li, Xue Yang, Feng Chen, Yanyan Zhang, Hongjun Li Chinese Medical Journal.2023; 136(22): 2706. CrossRef
Ketogenic Diets and Hepatocellular Carcinoma Yan Lan, Chaonan Jin, Pavitra Kumar, Xia Yu, Cameron Lenahan, Jifang Sheng Frontiers in Oncology.2022;[Epub] CrossRef
Prognostic significance of combined α-fetoprotein and CA19-9 for hepatocellular carcinoma after hepatectomy Jie Zhang, Shang Dong Qin, Yan Li, Fei Lu, Wen Feng Gong, Jian Hong Zhong, Liang Ma, Jing Fei Zhao, Guo Hua Zhan, Peng Zhan Li, Bin Song, Bang De Xiang World Journal of Surgical Oncology.2022;[Epub] CrossRef
Real-Life Experience of mTOR Inhibitors in Liver Transplant Recipients in a Region Where Living Donation Is Predominant Pil Soo Sung, Ji Won Han, Changho Seo, Joseph Ahn, Soon Kyu Lee, Hee Chul Nam, Ho Joong Choi, Young Kyoung You, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon Frontiers in Pharmacology.2021;[Epub] CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1 Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef
Does Neutrophil to Lymphocyte Ratio Have a Role in Identifying Cytokeratin 19-Expressing Hepatocellular Carcinoma? Chao-Wei Lee, Sey-En Lin, Ming-Chin Yu, Hao-Wei Kou, Cheng-Han Lee, Tony Kuo, Kuan-Chieh Lee, Hsin-I Tsai Journal of Personalized Medicine.2021; 11(11): 1078. CrossRef
Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma Soon Kyu Lee, Sung Won Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon International Journal of Molecular Sciences.2021; 22(19): 10271. CrossRef
First
Prev
